Skip to main content
OpenTrials
Completed

NCT Number: NCT04109404

Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin

Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Meningioma Central Nervous System Neoplasms Meningeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Département de Nutrition - CHRU de Brest

Brest, 29200, France

About this study

Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • minimum 18 years
  • medical follow up in CHRU of Brest
  • treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception
  • meningioma after treatement by progestin or CYPROTERONE ACETATE

Exclusion criteria

  • history ofbreast cancer
  • history of cerebral radiotherapy
  • history of neurofibromatosis
  • meningioma before treatement by progestin or CYPROTERONE ACETATE
  • minor patient

Treatment and study plan

Primary outcomes

  1. Diagnosis of meningiomas caracteristics

    Time frame: 12 months

    meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description

Secondary outcomes

  1. prescription status of progestogenic treatment

    Time frame: 12 months

    indications, duration of treatment, name and type of treatment

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin: Retrospective Study in Patients Followed at the CHRU of Brest

Acronym: MAP

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Sep 30, 2019
Registry last updated
Oct 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.